Raoul Bationo1,2, Ablassé Rouamba3, Abdoulaziz Diarra4, Monique Lydie Ahia Beugré-Kouassi2,5, Jean-Bertin Beugré2,5, Fabienne Jordana6. 1. CHU de Bogodogo, Ouagadougou, Burkina Faso. 2. Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire. 3. Laboratoire de Biochimie et Chimie Appliquées, Université Joseph Ki-Zerbo, Ouagadougou, Burkina Faso. 4. CHU de Tengandogo/UFR Sciences de la Santé, Université Joseph Ki-Zerbo, Ouagadougou, Burkina Faso. 5. Département d'Orthopédie Dento-Faciale - UFR d'Odonto-Stomatologie, Abidjan, Côte d'Ivoire. 6. Service d'Odontologie - CHU Nantes, UFR d'Odontologie de Nantes, Nantes, France.
Abstract
INTRODUCTION: The aim of this study was to determine the cytotoxicity of light-cured composite resins (Clearfil ES-2, Clearfil ES Flow, Filtek Supreme XTE, Grengloo, Blugloo, Transbond XT, and Transbond LR) then to assess leachable components in contact with human gingival fibroblasts (GFs) and to quantity detected bisphenol A (BPA). METHODS: Light-cured composite resin discs were immersed for 24 hours in gingival fibroblastic medium (n = 3 for each product) and in control medium (n = 2 for each product) contained in plate. Cytotoxicity of the products (n = 95) was determined by the measure of cell viability using MTT assay after reading the optical densities of the plates. The analysis of leachable components was done by gas phase chromatography and mass spectrometry (GC-MS) and detected BPA was quantified. The limit of quantification was 0.01 μg/mL. Statistical analyses were performed by using IBM SPSS Statistics 20 and Kruskal-Wallis and Mann-Whitney U-tests were applied. RESULTS: Cell viabilities were between 85 and 90%. Many chemical compounds including triethylene glycol dimethacrylate (TEGDMA) and BPA were identified. The average concentrations were 0.67 μg/mL ± 0.84 in the control medium and 0.73 μg/mL ± 1.05 in the fibroblastic medium. Filtek Supreme XTE presented the highest concentration of BPA with 2.16 μg/mL ± 0.65 and Clearfil ES Flow presented the lowest with 0.25 μg/mL ± 0.35. No BPA was detected with Transbond XT and Transbond LR. Clearfil ES Flow, Filtek Supreme XTE, Grengloo and Transbond LR presented residual TEGDMA. CONCLUSIONS: Light-cured composite resins are slightly cytotoxic opposite GFs and release many components including BPA and TEGDMA. Clinical precautions should be taken to decrease the release of these monomers.
INTRODUCTION: The aim of this study was to determine the cytotoxicity of light-cured composite resins (Clearfil ES-2, Clearfil ES Flow, Filtek Supreme XTE, Grengloo, Blugloo, Transbond XT, and Transbond LR) then to assess leachable components in contact with human gingival fibroblasts (GFs) and to quantity detected bisphenol A (BPA). METHODS: Light-cured composite resin discs were immersed for 24 hours in gingival fibroblastic medium (n = 3 for each product) and in control medium (n = 2 for each product) contained in plate. Cytotoxicity of the products (n = 95) was determined by the measure of cell viability using MTT assay after reading the optical densities of the plates. The analysis of leachable components was done by gas phase chromatography and mass spectrometry (GC-MS) and detected BPA was quantified. The limit of quantification was 0.01 μg/mL. Statistical analyses were performed by using IBM SPSS Statistics 20 and Kruskal-Wallis and Mann-Whitney U-tests were applied. RESULTS: Cell viabilities were between 85 and 90%. Many chemical compounds including triethylene glycol dimethacrylate (TEGDMA) and BPA were identified. The average concentrations were 0.67 μg/mL ± 0.84 in the control medium and 0.73 μg/mL ± 1.05 in the fibroblastic medium. Filtek Supreme XTE presented the highest concentration of BPA with 2.16 μg/mL ± 0.65 and Clearfil ES Flow presented the lowest with 0.25 μg/mL ± 0.35. No BPA was detected with Transbond XT and Transbond LR. Clearfil ES Flow, Filtek Supreme XTE, Grengloo and Transbond LR presented residual TEGDMA. CONCLUSIONS: Light-cured composite resins are slightly cytotoxic opposite GFs and release many components including BPA and TEGDMA. Clinical precautions should be taken to decrease the release of these monomers.
Authors: K L Van Landuyt; Tim Nawrot; B Geebelen; J De Munck; J Snauwaert; K Yoshihara; Hans Scheers; Lode Godderis; P Hoet; B Van Meerbeek Journal: Dent Mater Date: 2011-06-12 Impact factor: 5.304
Authors: F X Reichl; M Seiss; N Kleinsasser; K Kehe; K H Kunzelmann; P Thomas; W Spahl; R Hickel Journal: J Dent Res Date: 2008-04 Impact factor: 6.116
Authors: Athina A Bakopoulou; Ioanna N Triviai; Asterios S Tsiftsoglou; Paylos D Garefis Journal: Int J Prosthodont Date: 2006 Jan-Feb Impact factor: 1.681